Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Figlin

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Cancer|November 1, 1993
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumorsJ E Janik, M Sznol, W J Urba, et al.
Cancer Research|November 3, 2001
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factorC L Tso, A Zisman, A Pantuck, et al.
The Journal of Clinical Investigation|January 15, 1996
In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trialJ S Economou, A S Belldegrun, J Glaspy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancerF A Greco, R Figlin, M York, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinomaM H Voss, A Hussain, N Vogelzang, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Cancer|November 1, 1993
Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumorsJ E Janik, M Sznol, W J Urba, et al.
Cancer Research|November 3, 2001
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factorC L Tso, A Zisman, A Pantuck, et al.
The Journal of Clinical Investigation|January 15, 1996
In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trialJ S Economou, A S Belldegrun, J Glaspy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1996
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancerF A Greco, R Figlin, M York, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinomaM H Voss, A Hussain, N Vogelzang, et al.
Pageof 5